Next Article in Journal
Linkage of Infection to Adverse Systemic Complications: Periodontal Disease, Toll-Like Receptors, and Other Pattern Recognition Systems
Next Article in Special Issue
“Gnothi Seauton”: Leveraging the Host Response to Improve Influenza Virus Vaccine Efficacy
Previous Article in Journal / Special Issue
Efforts to Improve the Seasonal Influenza Vaccine
Review

New Kids on the Block: RNA-Based Influenza Virus Vaccines

1
PATH’s Center for Vaccine Innovation and Access, 455 Massachusetts Ave. NW, Suite 1000, Washington, DC 20001, USA
2
Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
*
Author to whom correspondence should be addressed.
Vaccines 2018, 6(2), 20; https://doi.org/10.3390/vaccines6020020
Received: 28 February 2018 / Revised: 21 March 2018 / Accepted: 27 March 2018 / Published: 1 April 2018
RNA-based immunization strategies have emerged as promising alternatives to conventional vaccine approaches. A substantial body of published work demonstrates that RNA vaccines can elicit potent, protective immune responses against various pathogens. Consonant with its huge impact on public health, influenza virus is one of the best studied targets of RNA vaccine research. Currently licensed influenza vaccines show variable levels of protection against seasonal influenza virus strains but are inadequate against drifted and pandemic viruses. In recent years, several types of RNA vaccines demonstrated efficacy against influenza virus infections in preclinical models. Additionally, comparative studies demonstrated the superiority of some RNA vaccines over the currently used inactivated influenza virus vaccines in animal models. Based on these promising preclinical results, clinical trials have been initiated and should provide valuable information about the translatability of the impressive preclinical data to humans. This review briefly describes RNA-based vaccination strategies, summarizes published preclinical and clinical data, highlights the roadblocks that need to be overcome for clinical applications, discusses the landscape of industrial development, and shares the authors’ personal perspectives about the future of RNA-based influenza virus vaccines. View Full-Text
Keywords: RNA vaccine; influenza virus; infectious disease; clinical trial RNA vaccine; influenza virus; infectious disease; clinical trial
MDPI and ACS Style

Scorza, F.B.; Pardi, N. New Kids on the Block: RNA-Based Influenza Virus Vaccines. Vaccines 2018, 6, 20. https://doi.org/10.3390/vaccines6020020

AMA Style

Scorza FB, Pardi N. New Kids on the Block: RNA-Based Influenza Virus Vaccines. Vaccines. 2018; 6(2):20. https://doi.org/10.3390/vaccines6020020

Chicago/Turabian Style

Scorza, Francesco B., and Norbert Pardi. 2018. "New Kids on the Block: RNA-Based Influenza Virus Vaccines" Vaccines 6, no. 2: 20. https://doi.org/10.3390/vaccines6020020

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop